Sino Biopharmaceutical to Distribute GSK's Hepatitis B Drug in China

MT Newswires Live

05/11

Sino Biopharmaceutical (HKG:1177) secured a supply deal for GlaxoSmithKline's hepatitis B drug, bepirovirsen, for China, according to a Monday filing with the Hong Kong bourse.

The firm's Chia Tai Tianqing Pharmaceutical Group entered into an exclusive strategic collaboration with GSK to cover the importation and distribution of bepirovirsen in mainland China for an initial term of 5.5 years at launch.

Sino Biopharmaceutical's shares were up nearly 2% in midday trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2634713684"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634713684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634713684?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 12:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634713684","market":"sg","top_or_hot":-1,"title":"Sino Biopharmaceutical to Distribute GSK's Hepatitis B Drug in China","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> (HKG:1177) secured a supply deal for GlaxoSmithKline's hepatitis B drug, bepirovirsen, for China, according to a Monday filing with the Hong Kong bourse.</p><p>The firm's Chia Tai Tianqing Pharmaceutical Group entered into an exclusive strategic collaboration with GSK to cover the importation and distribution of bepirovirsen in mainland China for an initial term of 5.5 years at launch.</p><p><a href=\"https://laohu8.com/S/SBMFF\">Sino Biopharmaceutical</a>'s shares were up nearly 2% in midday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical to Distribute GSK's Hepatitis B Drug in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical to Distribute GSK's Hepatitis B Drug in China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-05-11 12:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> (HKG:1177) secured a supply deal for GlaxoSmithKline's hepatitis B drug, bepirovirsen, for China, according to a Monday filing with the Hong Kong bourse.</p><p>The firm's Chia Tai Tianqing Pharmaceutical Group entered into an exclusive strategic collaboration with GSK to cover the importation and distribution of bepirovirsen in mainland China for an initial term of 5.5 years at launch.</p><p><a href=\"https://laohu8.com/S/SBMFF\">Sino Biopharmaceutical</a>'s shares were up nearly 2% in midday trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2634713684","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634713684","pubTimestamp":1778474442,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sino Biopharmaceutical  secured a supply deal for GlaxoSmithKline's hepatitis B drug, bepirovirsen, for China, according to a Monday filing with the Hong Kong bourse.The firm's Chia Tai Tianqing Pharmaceutical Group entered into an exclusive strategic collaboration with GSK to cover the importation and distribution of bepirovirsen in mainland China for an initial term of 5.5 years at launch.Sino Biopharmaceutical's shares were up nearly 2% in midday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","01177":"中国生物制药","BK4007":"制药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1521":"挪威政府全球养老基金持仓","BK1589":"北水核心资产","BK4532":"文艺复兴科技持仓","GSK.UK":"葛兰素史克","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","GSK":"葛兰素史克","GSKH":"GSK plc ADRhedged","BK4588":"碎股","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc"},"translate_title":"中国生物制药将在中国分销葛兰素史克乙肝药物","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":0.6,"GSK.UK":0.6,"01177":1,"GSK":1.5},"content_text":"Sino Biopharmaceutical (HKG:1177) secured a supply deal for GlaxoSmithKline's hepatitis B drug, bepirovirsen, for China, according to a Monday filing with the Hong Kong bourse.The firm's Chia Tai Tianqing Pharmaceutical Group entered into an exclusive strategic collaboration with GSK to cover the importation and distribution of bepirovirsen in mainland China for an initial term of 5.5 years at launch.Sino Biopharmaceutical's shares were up nearly 2% in midday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}